Affiliation:
1. Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China
2. Department of Biochemistry and Molecular Biology, School of Medicine University of Maryland Baltimore USA
3. Laboratory of Thoracic Surgery, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China
Abstract
ABSTRACTBackgroundBazedoxifene is a third‐generation selective estrogen receptor modulator that inhibits the IL6/IL6R/GP130 signaling pathway by inhibiting IL6‐induced homodimerization of GP130. Considering that the IL6/IL6R/GP130 signaling pathway is important in tumorigenesis and metastasis, bazedoxifene is thought to have an antitumor effect, which has been proven preliminarily in breast cancer and pancreatic cancer but has not yet been studied in non–small cell lung cancer (NSCLC). This study is aimed at evaluating the antitumor effect of bazedoxifene in NSCLC.MethodsA549 and H1299 NSCLC cell lines were employed and exposed to various concentrations of bazedoxifene, paclitaxel, gemcitabine, and their combinations for cell viability, colony formation, and wound healing assays to demonstrate the antitumor effect of bazedoxifene with or without paclitaxel or gemcitabine.ResultsMTT cell viability, colony formation, and wound healing assays showed that bazedoxifene was capable of inhibiting cell viability, colony formation, and cell migration in a dose‐dependent manner. In addition, bazedoxifene was capable of working with paclitaxel or gemcitabine synergistically to inhibit cell viability, colony formation, and cell migration.ConclusionThis study demonstrated the potential antitumor effect of bazedoxifene and its ability to improve the treatment efficacy of paclitaxel and gemcitabine.